BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 29669936)

  • 21. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
    Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
    Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.
    Helman SR; Stevanovic S; Campbell TE; Kwong MLM; Doran SL; Faquin WC; Hinrichs CS
    JAMA Netw Open; 2018 Jul; 1(3):e180706. PubMed ID: 30646017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.
    Perez Castro S; Iñarrea Fernández A; Lamas González MJ; Sarán Diez MT; Cid Lama A; Alvarez Martín MJ; Pato Mosquera M; López-Miragaya I; Estévez N; Torres Piñón J; Oña Navarro M
    J Med Virol; 2013 Jun; 85(6):1063-8. PubMed ID: 23588733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.
    Trimble CL; Clark RA; Thoburn C; Hanson NC; Tassello J; Frosina D; Kos F; Teague J; Jiang Y; Barat NC; Jungbluth AA
    J Immunol; 2010 Dec; 185(11):7107-14. PubMed ID: 21037100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
    Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
    J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
    Nindl I; Rindfleisch K; Lotz B; Schneider A; Dürst M
    Int J Cancer; 1999 Jul; 82(2):203-7. PubMed ID: 10389753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonality analysis and human papillomavirus infection in squamous metaplasia and atypical immature metaplasia of uterine cervix: is atypical immature metaplasia a precursor to cervical intraepithelial neoplasia 3?
    Miyatake T; Ueda Y; Yoshino K; Shroyer KR; Kanao H; Sun H; Nakashima R; Kimura T; Wakasa T; Enomoto T
    Int J Gynecol Pathol; 2007 Apr; 26(2):180-7. PubMed ID: 17413987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis.
    Leung TW; Liu SS; Leung RC; Chu MM; Cheung AN; Ngan HY
    J Med Virol; 2015 Jun; 87(6):1022-33. PubMed ID: 25648229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
    J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.
    Gosmann C; Mattarollo SR; Bridge JA; Frazer IH; Blumenthal A
    J Immunol; 2014 Sep; 193(5):2248-57. PubMed ID: 25063870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.
    Maldonado L; Teague JE; Morrow MP; Jotova I; Wu TC; Wang C; Desmarais C; Boyer JD; Tycko B; Robins HS; Clark RA; Trimble CL
    Sci Transl Med; 2014 Jan; 6(221):221ra13. PubMed ID: 24477000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1.
    Liu H; Xu J; Yang Y; Wang X; Wu E; Majerciak V; Zhang T; Steenbergen RDM; Wang HK; Banerjee NS; Li Y; Lu W; Meyers C; Zhu J; Xie X; Chow LT; Zheng ZM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33436409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran.
    Heydari N; Oskouee MA; Vaezi T; Shoja Z; Esmaeili HA; Hamkar R; Shahmahmoodi S; Jalilvand S
    J Med Virol; 2018 Jan; 90(1):172-176. PubMed ID: 28786495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
    Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
    J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding HLA-G driven journey from HPV infection to cancer cervix: Adding missing pieces to the jigsaw puzzle.
    Aggarwal R; Sharma M; Mangat N; Suri V; Bhatia T; Kumar P; Minz R
    J Reprod Immunol; 2020 Nov; 142():103205. PubMed ID: 33099242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.